Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study

NCT01280747 is registered in ClinicalTrials.gov with Pfizer's Upjohn has merged with Mylan to form Viatris Inc. as lead sponsor.

NCT NCT01280747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01280747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase
Observational
Overall status
Terminated
Start date
January 31, 2011
Completion date
April 30, 2012
Enrollment
42 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

fibromyalgia, painful diabetic peripheral neuropathy